Answers are grounded in this paper and cite their sources.
Uncovers how sulfonylurea receptor binding triggers insulin release in beta-cells, highlighting mechanisms behind familial hyperinsulinism and systemic adverse effects.
Binding of hypoglycemic sulfonylureas and their analogues to the sulfonylurea receptor in the beta-cell plasma membrane mediates closure of the ATP-sensitive K+-channel (KATP-channel) and thereby stimulation of insulin release. The sulfonylurea receptor is a member of the traffic ATPase family with two intracellular nucleotide binding folds. The receptor binding site for hypoglycemic drugs is located at the cytoplasmic face of the plasma membrane. Mutations in the sulfonylurea receptor gene have been detected which cause familial hyper-insulinism. Non-beta-cell sulfonylurea receptors do not contribute to the therapeutic benefit of sulfonylureas, but might be involved in presumed adverse effects of sulfonylureas in the cardiovascular and the central nervous system.
No takes yet. Share an insight, caveat, or question.
Panten et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: